© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
April 26, 2021
Ajeet Gajra, MD, MBBS, FACP, talks about identifying and removing the barriers for offering CAR T-cell therapy at the community practice level.
March 20, 2021
Penn Medicine's Stephen Schuster, MD, offers an overview of an eventful year in CAR T-cell therapy at the NCCN Virtual Annual Meeting.
February 05, 2021
A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.
January 25, 2021
January 20, 2021
Exciting new and ongoing developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 62nd American Society of Hematology (ASH) annual meeting.
December 28, 2020
Gene-editing therapy in sickle cell disease and advances in multiple myeloma dominated hematology news in 2020.
December 24, 2020
Readers favored news about ibrutinib, the first chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma, and the effect of the pandemic on patients with chronic lymphocytic leukemia.
December 21, 2020
Results presented earlier this month at ASH showed a 97% overall response rate, and progression-free survival had not been reached.
December 05, 2020
Results were released for a leading chimeric antigen receptor (CAR) T-cell therapy candidate in multiple myeloma, along with long-term findings for an early treatment that may soon face competition.
December 04, 2020
A preview of the 62nd annual American Society of Hematology meeting, taking place in a virtual format.